Catch up on all H3 news and developments regarding research, ongoing trials and personnel.
Press Releases
February 19, 2020
H3 Biomedicine Announces Appointment of Chief Medical Officer, Antonio Gualberto
Industry veteran to helm newly created position as H3 advances oncology pipeline Read More
May 16, 2019
H3 Biomedicine to Present Data from Two Ongoing Precision Medicine Clinical Programs at 2019 ASCO Annual Meeting
Phase 1 dose escalation of H3B-6545, a potential first-in-class Selective ERα Covalent Antagonist (SERCA), in women with ER-positive, HER2-negative breast… Read More
March 25, 2019
H3 Biomedicine Announces Multiple Presentations at Upcoming AACR Annual Meeting
Presentations highlight company’s expertise seamlessly integrating human biology, data science and modern chemistry to advance a pipeline of investigational breakthrough… Read MoreIn the News
Fierce Biotech
Chutes & Ladders
Welcome to this week's Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Read More
Endpoints News
Antonio Gualberto starts post-Kura career at Eisai subsidiary H3
Days after Kura Oncology announced the departure of co-founder Antonio Gualberto, we finally know where he wound up. Read More
STAT
Up and down the ladder: The latest comings and goings
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Read More
BioSpace
BioSpace Movers & Shakers
H3, a subsidiary of Eisai Co., named Antonio Gualberto as its new CMO. Gualberto will oversee global clinical research &… Read More
The Pharma Letter
Eisai subsidiary names Antonio Gualberto as CMO
H3 Biomedicine, the USA-based precision medicine subsidiary of Japanese drugmaker Eisai, has named industry Read More
Fierce Biotech
Eisai unit H3 Biomedicine poaches Kura Oncology founder as CMO
Antonio Gualberto, M.D., Ph.D., helped found early-stage biotech Kura Oncology and ran its R&D as chief medical officer. Read More
BioPharm Insight
H3 Biomedicine in active discussions for co-developing its cancer genomics programs – CEO
H3 Biomedicine is in talks with pharma companies to co-develop one or more of its Phase I drugs that are… Read More
Boston Business Journal
H3 Biomedicine to Begin Trials of First-Ever Gene-Splicing Cancer Drug
Kendall Square-based cancer biotech H3 Biomedicine, created five years ago by Japanese drug firm Eisai, will bring its first drug… Read More
PharmaVOICE
H3 Biomedicine’s Dr. Lihua Yu Honored in PharmaVOICE 100
In her position as VP, data science and information technology, at H3 Biomedicine, Lihua Yu, Ph.D., is driving the expanded… Read More
Boston Business Journal
Foundation Medicine, H3 Biomedicine Partner to Develop Cancer Drugs
A partnership announced today between two Cambridge companies, Foundation Medicine (Nasdaq: FMI) and H3 Biomedicine, is further evidence of the… Read More
FasterCures
Fixes in Financing
High-risk, long-term investments are needed to turn medical innovations into lifesaving therapies. At FasterCures, we examine and highlight innovative funding mechanisms… Read More
European Business Review
Personal Medicine
Biomarker research is fundamental to the delivery of targeted therapeutics. An industry shift towards a more collaborative approach to patient-derived… Read More
Company
Information
H3 Biomedicine was founded in 2011 as a research and development engine focused on advancing drugs from bench to bedside.
For all media interested in speaking to members of H3 Biomedicine’s team, or receiving further information about the company or pipeline, please contact us.